US Patent

US7928115 — Methods of treating travelers diarrhea and hepatic encephalopathy

Method of Use · Assigned to Salix Pharmaceuticals Ltd · Expires 2029-07-24 · 3y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating traveler's diarrhea in subjects with hepatic encephalopathy using the drug rifaximin.

USPTO Abstract

Treatment of traveler's diarrhea in subjects having hepatic encephalopathy using rifaximin is disclosed.

Drugs covered by this patent

Xifaxan (rifaximin) · Bausch Health

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1121`	—	Xifaxan

Patent Metadata

Patent number: US7928115
Jurisdiction: US
Classification: Method of Use
Expires: 2029-07-24
Drug substance claim: No
Drug product claim: No
Assignee: Salix Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.